Mild Cognitive Impairment - Pipeline Review, H2 2015

1
Mild Cognitive Impairment - Pipeline Review, H2
2015
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
TELEPHONE [phone]E-MAIL
sales_at_researchbeam.com
Published on Oct 2014
2


Report Overview

• Scope
• The report provides a snapshot of the global
  therapeutic landscape of Mild cognitive
  impairment
• The report reviews key pipeline products under
  drug profile section which includes, product
  description, MoA and RD brief, licensing and
  collaboration details other developmental
  activities
• The report reviews key players involved in the
  therapeutics development for Mild cognitive
  impairment and enlists all their major and minor
  projects
• The report summarizes all the dormant and
  discontinued pipeline projects
• A review of the Mild cognitive impairment
  products under development by companies and
  universities/research institutes based on
  information derived from company and
  industry-specific sources Pipeline products
  coverage based on various stages of development
  ranging from pre-registration till discovery and
  undisclosed stages
• A detailed assessment of monotherapy and
  combination therapy pipeline projects
• Coverage of the Mild cognitive impairment
  pipeline on the basis of target, MoA, route of
  administration and molecule type Latest news and
  deals relating related to pipeline products
• Read More At http//www.researchbeam.com/mild-co
  gnitive-impairment-pipeline-review-h2-2015-market

3


Table of Content
Table of Contents 2List of Tables 6List of
Figures 7Introduction 8Global Markets Direct
Report Coverage 8Mild Cognitive Impairment
Overview 9Therapeutics Development 10Pipeline
Products for Mild Cognitive Impairment - Overview
10Pipeline Products for Mild Cognitive
Impairment - Comparative Analysis 11Mild
Cognitive Impairment - Therapeutics under
Development by Companies 12Mild Cognitive
Impairment - Therapeutics under Investigation by
Universities/Institutes 13Mild Cognitive
Impairment - Pipeline Products Glance 14Clinical
Stage Products 14Early Stage Products 15Mild
Cognitive Impairment - Products under Development
by Companies 16Mild Cognitive Impairment -
Products under Investigation by
Universities/Institutes 17Mild Cognitive
Impairment - Companies Involved in Therapeutics
Development 18Actinogen Limited 18Avraham
Pharmaceuticals Ltd. 19Boehringer Ingelheim GmbH
20CereSpir Incorporated 21D-Pharm Ltd. 22
4


Report Overview
Reasons to buy Provides strategically
significant competitor information, analysis, and
insights to formulate effective RD development
strategies Identify emerging players with
potentially strong product portfolio and create
effective counter-strategies to gain competitive
advantage Develop strategic initiatives by
understanding the focus areas of leading
companies Identify and understand important and
diverse types of therapeutics under development
for Mild cognitive impairment Plan mergers and
acquisitions effectively by identifying key
players of the most promising pipeline Devise
corrective measures for pipeline projects by
understanding Mild cognitive impairment pipeline
depth and focus of Indication therapeutics
Develop and design in-licensing and
out-licensing strategies by identifying
prospective partners with the most attractive
projects to enhance and expand business potential
and Scope Modify the therapeutic portfolio by
identifying discontinued projects and
understanding the factors that drove them from
pipeline Enquire At http//www.researchbeam.c
om/mild-cognitive-impairment-pipeline-review-h2-20
15-market/enquire-about-report
5



FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/mild-cognitive-impairm
ent-pipeline-review-h2-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com